Erica Seiguer Shenoy, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Penicillins | 16 | 2020 | 405 | 4.290 |
Why?
|
Drug Hypersensitivity | 20 | 2020 | 922 | 4.140 |
Why?
|
Infection Control | 16 | 2024 | 985 | 3.390 |
Why?
|
Cross Infection | 13 | 2023 | 1425 | 2.440 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 9 | 2017 | 704 | 2.230 |
Why?
|
Anti-Bacterial Agents | 26 | 2024 | 7471 | 2.220 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 5 | 2022 | 250 | 2.120 |
Why?
|
Staphylococcal Infections | 10 | 2016 | 1412 | 1.710 |
Why?
|
beta-Lactams | 6 | 2019 | 159 | 1.480 |
Why?
|
Health Personnel | 8 | 2024 | 3384 | 1.480 |
Why?
|
Occupational Exposure | 3 | 2023 | 1818 | 1.210 |
Why?
|
Masks | 2 | 2020 | 215 | 1.150 |
Why?
|
Occupational Health | 3 | 2021 | 814 | 1.070 |
Why?
|
Communicable Diseases | 4 | 2024 | 875 | 1.030 |
Why?
|
Enterococcus | 3 | 2017 | 159 | 0.980 |
Why?
|
Organizational Policy | 3 | 2021 | 434 | 0.980 |
Why?
|
Pandemics | 13 | 2024 | 8753 | 0.960 |
Why?
|
Communicable Disease Control | 3 | 2020 | 857 | 0.910 |
Why?
|
Carbapenems | 2 | 2022 | 125 | 0.890 |
Why?
|
Post-Exposure Prophylaxis | 2 | 2022 | 113 | 0.890 |
Why?
|
Bedding and Linens | 1 | 2023 | 41 | 0.840 |
Why?
|
Hospitals, General | 3 | 2021 | 807 | 0.830 |
Why?
|
Gram-Positive Bacterial Infections | 3 | 2014 | 342 | 0.800 |
Why?
|
Bacteriological Techniques | 2 | 2014 | 277 | 0.800 |
Why?
|
Penile Diseases | 1 | 2022 | 47 | 0.790 |
Why?
|
Equipment Contamination | 2 | 2023 | 183 | 0.780 |
Why?
|
Cephalosporins | 4 | 2019 | 200 | 0.780 |
Why?
|
Disinfection | 1 | 2023 | 207 | 0.760 |
Why?
|
Gene Transfer, Horizontal | 1 | 2022 | 149 | 0.750 |
Why?
|
Anthozoa | 1 | 2021 | 65 | 0.740 |
Why?
|
Methicillin | 4 | 2017 | 62 | 0.740 |
Why?
|
Sequence Analysis | 1 | 2021 | 240 | 0.740 |
Why?
|
Hemorrhagic Fevers, Viral | 1 | 2021 | 23 | 0.740 |
Why?
|
Exanthema | 2 | 2024 | 504 | 0.740 |
Why?
|
Rectal Diseases | 1 | 2022 | 142 | 0.730 |
Why?
|
Skin Ulcer | 1 | 2022 | 131 | 0.730 |
Why?
|
Asymptomatic Infections | 2 | 2021 | 134 | 0.720 |
Why?
|
Guideline Adherence | 4 | 2023 | 2239 | 0.720 |
Why?
|
Skin Tests | 10 | 2020 | 639 | 0.720 |
Why?
|
Disease Outbreaks | 7 | 2024 | 1764 | 0.710 |
Why?
|
Travel Medicine | 1 | 2020 | 83 | 0.680 |
Why?
|
Acinetobacter Infections | 1 | 2020 | 73 | 0.660 |
Why?
|
Coronavirus Infections | 4 | 2020 | 3116 | 0.660 |
Why?
|
Urinalysis | 1 | 2021 | 369 | 0.650 |
Why?
|
Urologic Diseases | 1 | 2021 | 247 | 0.640 |
Why?
|
Duodenoscopes | 1 | 2019 | 43 | 0.630 |
Why?
|
Surgical Wound Infection | 2 | 2018 | 1544 | 0.630 |
Why?
|
Acinetobacter baumannii | 1 | 2020 | 123 | 0.630 |
Why?
|
Communicable Diseases, Emerging | 1 | 2020 | 149 | 0.630 |
Why?
|
Sentinel Surveillance | 2 | 2018 | 292 | 0.620 |
Why?
|
Hemorrhagic Fever, Ebola | 3 | 2021 | 424 | 0.620 |
Why?
|
Monkeypox virus | 3 | 2023 | 43 | 0.610 |
Why?
|
Decision Support Systems, Clinical | 4 | 2022 | 1176 | 0.610 |
Why?
|
Immunologic Tests | 1 | 2019 | 104 | 0.600 |
Why?
|
Vancomycin | 3 | 2018 | 506 | 0.600 |
Why?
|
Drug Resistance, Multiple, Bacterial | 2 | 2020 | 590 | 0.590 |
Why?
|
Polymerase Chain Reaction | 4 | 2015 | 6091 | 0.580 |
Why?
|
DNA Primers | 1 | 2021 | 2826 | 0.570 |
Why?
|
Klebsiella pneumoniae | 1 | 2019 | 252 | 0.550 |
Why?
|
Ventilator-Induced Lung Injury | 1 | 2018 | 135 | 0.550 |
Why?
|
Delivery of Health Care | 10 | 2024 | 5367 | 0.540 |
Why?
|
Hypersensitivity | 3 | 2021 | 1172 | 0.540 |
Why?
|
Viral Vaccines | 2 | 2021 | 596 | 0.530 |
Why?
|
Massachusetts | 10 | 2023 | 8908 | 0.520 |
Why?
|
Ventilators, Mechanical | 1 | 2018 | 292 | 0.510 |
Why?
|
Hepatitis B | 1 | 2021 | 707 | 0.510 |
Why?
|
Humans | 97 | 2024 | 768451 | 0.510 |
Why?
|
Pneumonia, Staphylococcal | 1 | 2015 | 39 | 0.510 |
Why?
|
Influenza A Virus, H3N2 Subtype | 1 | 2015 | 85 | 0.500 |
Why?
|
Preoperative Care | 2 | 2021 | 2257 | 0.500 |
Why?
|
Mass Screening | 4 | 2020 | 5455 | 0.490 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 3240 | 0.480 |
Why?
|
Vancomycin Resistance | 2 | 2012 | 125 | 0.480 |
Why?
|
Disease Transmission, Infectious | 1 | 2020 | 562 | 0.480 |
Why?
|
Herpes Simplex | 2 | 2024 | 470 | 0.470 |
Why?
|
Workplace | 1 | 2020 | 872 | 0.450 |
Why?
|
Health Facilities | 3 | 2023 | 576 | 0.440 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2021 | 952 | 0.440 |
Why?
|
Patient Transfer | 2 | 2017 | 796 | 0.420 |
Why?
|
Epidemiologic Methods | 1 | 2018 | 1337 | 0.420 |
Why?
|
Antibiotic Prophylaxis | 1 | 2018 | 640 | 0.410 |
Why?
|
Hepatitis C | 1 | 2021 | 1594 | 0.370 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2020 | 2181 | 0.370 |
Why?
|
Meningitis, Viral | 1 | 2011 | 50 | 0.370 |
Why?
|
Nasal Mucosa | 1 | 2014 | 412 | 0.360 |
Why?
|
Carrier State | 1 | 2014 | 529 | 0.350 |
Why?
|
Influenza, Human | 2 | 2015 | 1540 | 0.340 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2013 | 614 | 0.300 |
Why?
|
Pain | 1 | 2022 | 5096 | 0.280 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 2011 | 558 | 0.250 |
Why?
|
United States | 18 | 2024 | 73121 | 0.250 |
Why?
|
Models, Theoretical | 1 | 2017 | 3590 | 0.250 |
Why?
|
Patient Admission | 1 | 2012 | 1370 | 0.240 |
Why?
|
Wrestling | 1 | 2024 | 19 | 0.230 |
Why?
|
Physicians | 1 | 2022 | 4615 | 0.230 |
Why?
|
Nafcillin | 2 | 2014 | 23 | 0.230 |
Why?
|
Data Collection | 3 | 2024 | 3329 | 0.230 |
Why?
|
Cefazolin | 2 | 2014 | 95 | 0.220 |
Why?
|
Clostridium Infections | 2 | 2022 | 559 | 0.220 |
Why?
|
Electronic Health Records | 5 | 2022 | 4877 | 0.220 |
Why?
|
Methicillin Resistance | 2 | 2015 | 198 | 0.220 |
Why?
|
Needlestick Injuries | 1 | 2023 | 71 | 0.210 |
Why?
|
Industry | 1 | 2005 | 366 | 0.210 |
Why?
|
Boston | 7 | 2021 | 9361 | 0.200 |
Why?
|
Practice Guidelines as Topic | 6 | 2021 | 7451 | 0.200 |
Why?
|
Vaccination | 4 | 2021 | 3434 | 0.200 |
Why?
|
Anus Diseases | 1 | 2022 | 54 | 0.200 |
Why?
|
Herpesvirus 2, Human | 2 | 2015 | 191 | 0.200 |
Why?
|
Nucleic Acid Amplification Techniques | 2 | 2021 | 333 | 0.200 |
Why?
|
Travel | 2 | 2020 | 800 | 0.200 |
Why?
|
Catheter-Related Infections | 2 | 2015 | 275 | 0.200 |
Why?
|
Financing, Government | 1 | 2005 | 473 | 0.190 |
Why?
|
Infectious Disease Transmission, Professional-to-Patient | 1 | 2021 | 33 | 0.180 |
Why?
|
Ulcer | 1 | 2022 | 204 | 0.180 |
Why?
|
Marburg Virus Disease | 1 | 2020 | 11 | 0.180 |
Why?
|
Female | 29 | 2023 | 396943 | 0.180 |
Why?
|
Respiratory Insufficiency | 2 | 2022 | 1244 | 0.180 |
Why?
|
Risk Assessment | 4 | 2023 | 24311 | 0.180 |
Why?
|
Contact Tracing | 1 | 2022 | 275 | 0.170 |
Why?
|
Patient Isolation | 1 | 2020 | 100 | 0.170 |
Why?
|
Male | 27 | 2024 | 364781 | 0.170 |
Why?
|
Burn Units | 1 | 2020 | 143 | 0.160 |
Why?
|
Patient Positioning | 1 | 2022 | 332 | 0.160 |
Why?
|
Odds Ratio | 3 | 2021 | 9687 | 0.160 |
Why?
|
Colistin | 1 | 2019 | 46 | 0.160 |
Why?
|
Quality Control | 1 | 2021 | 835 | 0.160 |
Why?
|
Urinary Tract Infections | 2 | 2015 | 806 | 0.160 |
Why?
|
Bacteremia | 2 | 2016 | 985 | 0.160 |
Why?
|
Infection Control Practitioners | 1 | 2018 | 12 | 0.160 |
Why?
|
Drug Resistance, Microbial | 1 | 2021 | 830 | 0.150 |
Why?
|
Herpesvirus 1, Human | 1 | 2024 | 744 | 0.150 |
Why?
|
Crohn Disease | 1 | 2011 | 2293 | 0.150 |
Why?
|
Drug Eruptions | 1 | 2021 | 335 | 0.150 |
Why?
|
Genome, Viral | 1 | 2021 | 673 | 0.150 |
Why?
|
Influenza Vaccines | 1 | 2005 | 781 | 0.150 |
Why?
|
Inpatients | 6 | 2019 | 2561 | 0.150 |
Why?
|
Retrospective Studies | 14 | 2023 | 81834 | 0.150 |
Why?
|
Amoxicillin | 1 | 2019 | 181 | 0.150 |
Why?
|
Clindamycin | 1 | 2018 | 139 | 0.140 |
Why?
|
Rectum | 1 | 2022 | 902 | 0.140 |
Why?
|
Immunization | 1 | 2021 | 1220 | 0.140 |
Why?
|
Staphylococcus aureus | 2 | 2016 | 1461 | 0.140 |
Why?
|
Lung | 1 | 2015 | 10090 | 0.140 |
Why?
|
Medication Therapy Management | 1 | 2018 | 131 | 0.140 |
Why?
|
Plasmids | 1 | 2022 | 2269 | 0.140 |
Why?
|
Intensive Care Units | 3 | 2020 | 3805 | 0.140 |
Why?
|
Workflow | 1 | 2021 | 861 | 0.140 |
Why?
|
Adult | 18 | 2022 | 223542 | 0.140 |
Why?
|
Research | 1 | 2005 | 1984 | 0.140 |
Why?
|
Syndrome | 1 | 2023 | 3278 | 0.130 |
Why?
|
Ebolavirus | 1 | 2019 | 250 | 0.130 |
Why?
|
United States Food and Drug Administration | 1 | 2005 | 1669 | 0.130 |
Why?
|
Middle Aged | 19 | 2022 | 223418 | 0.130 |
Why?
|
Community-Acquired Infections | 1 | 2020 | 473 | 0.130 |
Why?
|
Universal Precautions | 1 | 2015 | 34 | 0.130 |
Why?
|
Aged | 17 | 2022 | 171520 | 0.120 |
Why?
|
Microbial Sensitivity Tests | 2 | 2019 | 1965 | 0.120 |
Why?
|
Drug Prescriptions | 2 | 2015 | 1677 | 0.120 |
Why?
|
Fellowships and Scholarships | 1 | 2024 | 1134 | 0.120 |
Why?
|
HIV Infections | 1 | 2021 | 17564 | 0.120 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 749 | 0.120 |
Why?
|
Safety Management | 1 | 2020 | 764 | 0.120 |
Why?
|
Prospective Studies | 6 | 2022 | 54914 | 0.120 |
Why?
|
Natural Language Processing | 1 | 2023 | 1197 | 0.120 |
Why?
|
Antibodies, Monoclonal | 1 | 2011 | 9263 | 0.110 |
Why?
|
Anaphylaxis | 1 | 2021 | 758 | 0.110 |
Why?
|
Shock | 1 | 2015 | 316 | 0.110 |
Why?
|
Desensitization, Immunologic | 1 | 2019 | 563 | 0.110 |
Why?
|
Quality Assurance, Health Care | 1 | 2023 | 2179 | 0.110 |
Why?
|
Rectal Neoplasms | 1 | 2022 | 1179 | 0.110 |
Why?
|
RNA, Viral | 1 | 2021 | 2865 | 0.110 |
Why?
|
Decision Support Techniques | 2 | 2020 | 2010 | 0.100 |
Why?
|
Cohort Studies | 8 | 2021 | 41797 | 0.100 |
Why?
|
Vaccines | 1 | 2021 | 845 | 0.100 |
Why?
|
Guidelines as Topic | 2 | 2012 | 1395 | 0.100 |
Why?
|
Allergy and Immunology | 1 | 2014 | 175 | 0.100 |
Why?
|
Immunoglobulin E | 1 | 2019 | 1510 | 0.100 |
Why?
|
Professional Competence | 1 | 2015 | 431 | 0.100 |
Why?
|
Aged, 80 and over | 8 | 2022 | 59680 | 0.100 |
Why?
|
Risk Factors | 6 | 2023 | 74915 | 0.100 |
Why?
|
Nose | 1 | 2015 | 524 | 0.100 |
Why?
|
Education, Medical, Graduate | 1 | 2024 | 2411 | 0.090 |
Why?
|
Academic Medical Centers | 2 | 2020 | 2785 | 0.090 |
Why?
|
Education | 1 | 2014 | 536 | 0.090 |
Why?
|
Integrin alpha4 | 1 | 2011 | 88 | 0.090 |
Why?
|
Fatal Outcome | 1 | 2015 | 1840 | 0.090 |
Why?
|
Pregnancy | 4 | 2020 | 30179 | 0.090 |
Why?
|
Drug Utilization | 1 | 2017 | 1192 | 0.090 |
Why?
|
Herpesvirus 3, Human | 1 | 2011 | 159 | 0.090 |
Why?
|
Communication | 1 | 2024 | 3910 | 0.080 |
Why?
|
Prevalence | 3 | 2021 | 15880 | 0.080 |
Why?
|
Drug Industry | 2 | 2007 | 793 | 0.080 |
Why?
|
RNA, Messenger | 2 | 2021 | 12813 | 0.080 |
Why?
|
Hospital Administration | 1 | 2012 | 353 | 0.080 |
Why?
|
Pneumonia | 1 | 2020 | 2162 | 0.080 |
Why?
|
Policy | 1 | 2012 | 515 | 0.080 |
Why?
|
Diagnosis, Differential | 3 | 2024 | 13026 | 0.070 |
Why?
|
Critical Illness | 1 | 2021 | 2754 | 0.070 |
Why?
|
Containment of Biohazards | 2 | 2019 | 39 | 0.070 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2018 | 1418 | 0.070 |
Why?
|
Hospitalization | 3 | 2022 | 10845 | 0.070 |
Why?
|
Emergency Medical Services | 1 | 2019 | 1948 | 0.070 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2018 | 1401 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 3438 | 0.060 |
Why?
|
Hospitals | 4 | 2022 | 3906 | 0.060 |
Why?
|
Malaria | 1 | 2015 | 1240 | 0.060 |
Why?
|
Plasmodium falciparum | 1 | 2015 | 1746 | 0.060 |
Why?
|
Reproducibility of Results | 2 | 2021 | 20231 | 0.060 |
Why?
|
Sensitivity and Specificity | 3 | 2019 | 14728 | 0.060 |
Why?
|
Young Adult | 4 | 2024 | 60045 | 0.060 |
Why?
|
Legislation, Food | 1 | 2005 | 17 | 0.060 |
Why?
|
Suppuration | 1 | 2024 | 61 | 0.060 |
Why?
|
Radiography | 1 | 2015 | 6995 | 0.060 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2007 | 348 | 0.060 |
Why?
|
Mupirocin | 1 | 2024 | 55 | 0.060 |
Why?
|
Software | 1 | 2018 | 4463 | 0.060 |
Why?
|
Alzheimer Disease | 1 | 2005 | 8721 | 0.060 |
Why?
|
Federal Government | 1 | 2005 | 266 | 0.050 |
Why?
|
Biomedical Research | 1 | 2019 | 3463 | 0.050 |
Why?
|
Lymphocytes | 1 | 2011 | 2611 | 0.050 |
Why?
|
Legislation, Drug | 1 | 2005 | 216 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5532 | 0.050 |
Why?
|
Health Policy | 2 | 2024 | 2699 | 0.050 |
Why?
|
Administration, Topical | 1 | 2024 | 707 | 0.050 |
Why?
|
ROC Curve | 2 | 2022 | 3624 | 0.050 |
Why?
|
Length of Stay | 1 | 2016 | 6521 | 0.050 |
Why?
|
Pilot Projects | 1 | 2015 | 8730 | 0.050 |
Why?
|
Cross Reactions | 2 | 2014 | 828 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2022 | 15460 | 0.050 |
Why?
|
Prone Position | 1 | 2022 | 203 | 0.050 |
Why?
|
Long-Term Care | 1 | 2005 | 633 | 0.050 |
Why?
|
Policy Making | 1 | 2005 | 545 | 0.050 |
Why?
|
Marburgvirus | 1 | 2020 | 19 | 0.050 |
Why?
|
Seroepidemiologic Studies | 1 | 2022 | 406 | 0.040 |
Why?
|
Lymphocyte Activation | 1 | 2011 | 5495 | 0.040 |
Why?
|
Asia | 1 | 2021 | 627 | 0.040 |
Why?
|
Personnel, Hospital | 1 | 2021 | 285 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12096 | 0.040 |
Why?
|
Pharmaceutical Preparations | 1 | 2007 | 1089 | 0.040 |
Why?
|
Vaccines, Synthetic | 1 | 2021 | 622 | 0.040 |
Why?
|
Nausea | 1 | 2021 | 682 | 0.040 |
Why?
|
Area Under Curve | 1 | 2022 | 1640 | 0.040 |
Why?
|
Medicare | 2 | 2007 | 6881 | 0.040 |
Why?
|
Child | 3 | 2021 | 80863 | 0.040 |
Why?
|
Algorithms | 1 | 2018 | 14158 | 0.040 |
Why?
|
Time Factors | 2 | 2012 | 40271 | 0.040 |
Why?
|
Self Report | 2 | 2021 | 3771 | 0.030 |
Why?
|
Africa | 1 | 2019 | 726 | 0.030 |
Why?
|
Administration, Oral | 1 | 2024 | 4041 | 0.030 |
Why?
|
Outpatients | 2 | 2014 | 1607 | 0.030 |
Why?
|
Information Dissemination | 1 | 2024 | 1138 | 0.030 |
Why?
|
Cost of Illness | 1 | 2005 | 1960 | 0.030 |
Why?
|
Public Health Practice | 1 | 2017 | 221 | 0.030 |
Why?
|
Public Health Administration | 1 | 2017 | 242 | 0.030 |
Why?
|
Resource Allocation | 1 | 2017 | 353 | 0.030 |
Why?
|
Liberia | 1 | 2015 | 176 | 0.030 |
Why?
|
Internship and Residency | 1 | 2015 | 5952 | 0.030 |
Why?
|
Hypotension | 1 | 2021 | 888 | 0.030 |
Why?
|
Employment | 1 | 2021 | 1120 | 0.030 |
Why?
|
Models, Organizational | 1 | 2018 | 546 | 0.030 |
Why?
|
Risk Management | 1 | 2018 | 558 | 0.030 |
Why?
|
Intubation, Intratracheal | 1 | 2022 | 1359 | 0.030 |
Why?
|
Epidemics | 1 | 2019 | 517 | 0.030 |
Why?
|
Reference Values | 1 | 2020 | 4941 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2727 | 0.030 |
Why?
|
Caregivers | 1 | 2005 | 2302 | 0.030 |
Why?
|
Incidence | 2 | 2021 | 21552 | 0.030 |
Why?
|
Documentation | 1 | 2019 | 913 | 0.030 |
Why?
|
Animals | 2 | 2021 | 169418 | 0.030 |
Why?
|
Standard of Care | 1 | 2017 | 571 | 0.030 |
Why?
|
Professional Practice | 1 | 2014 | 314 | 0.020 |
Why?
|
Europe | 1 | 2019 | 3439 | 0.020 |
Why?
|
Public Health | 1 | 2005 | 2693 | 0.020 |
Why?
|
Societies, Medical | 1 | 2024 | 3955 | 0.020 |
Why?
|
Linear Models | 1 | 2022 | 5880 | 0.020 |
Why?
|
Medicaid | 1 | 2005 | 2843 | 0.020 |
Why?
|
Cesarean Section | 1 | 2020 | 1414 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2024 | 3063 | 0.020 |
Why?
|
Interprofessional Relations | 1 | 2017 | 997 | 0.020 |
Why?
|
Hospitals, Teaching | 1 | 2015 | 1158 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2022 | 2723 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3212 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2005 | 8051 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2659 | 0.020 |
Why?
|
Oxygen | 1 | 2019 | 4269 | 0.020 |
Why?
|
Fever | 1 | 2015 | 1622 | 0.020 |
Why?
|
Headache | 1 | 2015 | 1260 | 0.020 |
Why?
|
Malaria, Falciparum | 1 | 2015 | 1079 | 0.020 |
Why?
|
Disease Progression | 1 | 2024 | 13655 | 0.020 |
Why?
|
Formularies as Topic | 1 | 2007 | 94 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2019 | 5371 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2014 | 1600 | 0.010 |
Why?
|
Cardiac Surgical Procedures | 1 | 2020 | 3682 | 0.010 |
Why?
|
Body Mass Index | 1 | 2022 | 13030 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2021 | 22293 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2024 | 65409 | 0.010 |
Why?
|
Prognosis | 1 | 2022 | 30028 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 2007 | 1670 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26351 | 0.010 |
Why?
|
Models, Statistical | 1 | 2015 | 5103 | 0.010 |
Why?
|
Models, Biological | 1 | 2015 | 9505 | 0.010 |
Why?
|
Adolescent | 1 | 2022 | 89168 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2014 | 39430 | 0.010 |
Why?
|